Antiplatelet therapy: targeting the TxA2 pathway.

@article{Fontana2014AntiplateletTT,
  title={Antiplatelet therapy: targeting the TxA2 pathway.},
  author={Pierre Fontana and Anne Zufferey and Youssef Daali and Jean-Luc Reny},
  journal={Journal of cardiovascular translational research},
  year={2014},
  volume={7 1},
  pages={29-38}
}
The thromboxane (Tx) A2 pathway is a major contributor to the amplification of the initial platelet activation process. TxA2 mediates its effect through the thromboxane prostanoid (TP) receptor that is expressed not only in platelets, but also in endothelial cells, macrophages, and monocytes, and thus contributes to the development of atherosclerotic lesions. The TxA2 pathway is therefore a major target in the treatment of cardiovascular disease. Aspirin-the most widely used antiplatelet drug… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
mediates its effect through the thromboxane prostanoid ( TP ) receptor that is expressed not only in platelets , but also in endothelial cells , macrophages , and monocytes , and thus contributes to the development of atherosclerotic lesions .
mediates its effect through the thromboxane prostanoid ( TP ) receptor that is expressed not only in platelets , but also in endothelial cells , macrophages , and monocytes , and thus contributes to the development of atherosclerotic lesions .
mediates its effect through the thromboxane prostanoid ( TP ) receptor that is expressed not only in platelets , but also in endothelial cells , macrophages , and monocytes , and thus contributes to the development of atherosclerotic lesions .
All Topics